How Cancer Cells Hijack DNA Sensing to Evade the Immune System
A 2025 Molecular Cell review reveals how genomically unstable cancers exploit cGAS-STING regulation to escape immune detection.
Summary
Genomic instability is a hallmark of cancer, generating cytosolic DNA fragments that can trigger the cGAS-STING innate immune pathway. This 2025 review from Memorial Sloan Kettering synthesizes recent discoveries about how cancer cells both activate and suppress this pathway. Key topics include the sources of immunostimulatory DNA—such as micronuclei and extrachromosomal DNA (ecDNA)—and regulatory mechanisms like chromatin-mediated cGAS suppression and the exonuclease TREX1, which cancer cells may co-opt to degrade cytosolic DNA and avoid immune surveillance. Understanding these dynamics opens new therapeutic windows for reactivating antitumor immunity in genomically unstable cancers.
Detailed Summary
Genomic instability is one of the most defining features of cancer cells, driving tumor evolution, treatment resistance, and metastatic potential. However, this same instability creates an immunological vulnerability: fragmented or mislocalized DNA can leak into the cytoplasm, where it is recognized by cGAS (cyclic GMP-AMP synthase). cGAS produces the second messenger cGAMP, which activates STING (Stimulator of Interferon Genes), triggering innate immune responses including type I interferon production and inflammatory signaling. This review, published in Molecular Cell in October 2025 by Shim, Chen, and Maciejowski at Memorial Sloan Kettering, comprehensively synthesizes the current state of knowledge on how the cGAS-STING axis is activated and regulated specifically within cancer cells.
The authors examine the major sources of cytosolic DNA in genomically unstable cancers. Micronuclei—small membrane-bound compartments containing lagging chromosomes or chromosomal fragments—are highlighted as a primary source. When micronuclear envelopes rupture, their DNA contents are exposed to cytoplasmic cGAS. Extrachromosomal DNA (ecDNA), increasingly recognized as a driver of oncogene amplification, also represents a potentially immunostimulatory species. Additionally, DNA from mitochondria, replication stress, and double-strand break repair intermediates contribute to the cytosolic DNA pool.
A central theme of the review is the complex regulation that modulates whether cytosolic DNA actually triggers immune activation. Chromatin-mediated suppression of cGAS is discussed as a key mechanism: nucleosome-bound DNA is poorly sensed by cGAS, meaning the chromatin state of cytosolic DNA influences its immunogenicity. The exonuclease TREX1 receives particular attention as a molecule that degrades cytosolic DNA before it can activate cGAS. Cancer cells may upregulate TREX1 to neutralize the immunostimulatory potential of their own genomic debris, effectively shielding themselves from innate immune detection. Autophagy pathways are also noted as modulators of cytosolic DNA clearance.
Therapeutically, the review frames these regulatory mechanisms as actionable targets. Inhibiting TREX1, blocking chromatin-mediated cGAS suppression, or otherwise tipping the balance toward cGAS-STING activation in tumors could restore immune surveillance and synergize with existing immunotherapies such as immune checkpoint blockade. The authors note that the lead author's laboratory holds pending patents for targeting the cGAS-STING pathway in cancer, reflecting the translational urgency of this area.
Importantly, this is a review article, meaning it synthesizes and interprets published findings rather than presenting new primary experimental data. Its strength lies in organizing a rapidly evolving field into a coherent framework. Caveats include the inherent complexity of the cGAS-STING axis, context-dependency across tumor types, and the dual role of chronic STING signaling, which in some contexts promotes tumor-intrinsic pro-survival or pro-metastatic NF-κB signaling rather than antitumor immunity.
Key Findings
- Micronuclei rupture is a primary mechanism releasing genomic DNA into the cytoplasm to activate cGAS-STING.
- Extrachromosomal DNA (ecDNA) in cancer cells may represent an underappreciated immunostimulatory cytosolic DNA source.
- TREX1 exonuclease can be co-opted by cancer cells to degrade cytosolic DNA and evade cGAS-STING-mediated immune detection.
- Chromatin state of cytosolic DNA modulates cGAS activation; nucleosome-bound DNA is poorly sensed.
- Targeting TREX1 or chromatin-mediated cGAS suppression may restore antitumor immunity in genomically unstable cancers.
Methodology
This is a narrative review article published in Molecular Cell, synthesizing published primary literature on cGAS-STING signaling in cancer. No new experimental data were generated; the authors integrate findings from structural biology, cell biology, and cancer genomics studies. The review is authored by researchers at Memorial Sloan Kettering Cancer Center with disclosed patents in the field.
Study Limitations
As a review, this paper presents no new primary data and conclusions depend on interpretation of heterogeneous prior studies. The cGAS-STING pathway has context-dependent, sometimes pro-tumorigenic roles (e.g., NF-κB-driven metastasis), complicating therapeutic targeting. Translational relevance across diverse cancer types and patient populations remains to be validated in clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: